Teyro Labs Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Teyro Labs Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $1.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Teyro Labs Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $1.3M Trade | TransData Nexus

Teyro Labs Private Limited

Indian Pharmaceutical Exporter · Oncology Specialist · $1.3M Total Trade · DGFT Verified

Teyro Labs Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.3M across 3 products in 2 therapeutic categories. Based on 39 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Carboplatin ($934.6K), Pazopanib ($282.3K), Sunitinib ($89.5K).

Teyro Labs Private Limited — Export Portfolio & Destination Treemap

Teyro Labs Private Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Teyro Labs Private Limited? — Company Overview & Market Position

Teyro Labs Private Limited, established on February 21, 2014, is a privately held pharmaceutical company headquartered in Chennai, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U24100TN2014PTC095150. As of the latest available data, Teyro Labs has an authorized capital of ₹40.00 crore and a paid-up capital of ₹36.65 crore. The company employs approximately 175 professionals, reflecting its commitment to growth and operational excellence.

Teyro Labs specializes in the development and manufacturing of pharmaceutical formulations, with a particular focus on oncology products. The company's product portfolio includes finished pharmaceutical formulations such as tablets, capsules, syrups, and injections, catering to both domestic and international markets. Teyro Labs has achieved significant growth, with a 498.07% increase in total revenue and a 503.79% increase in net worth in the financial year ending March 31, 2024.

What Does Teyro Labs Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Carboplatin$934.6K 2

Product Portfolio — Top 3 by Export Value

Teyro Labs Private Limited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Carboplatin	Oncology	$934.6K	27	1.3%	13
2	Pazopanib	Advanced Oncology	$282.3K	6	3.4%	3
3	Sunitinib	Advanced Oncology	$89.5K	6	0.1%	9

Teyro Labs Private Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $1.3M. The top category is Oncology (71.5% of portfolio), followed by Advanced Oncology (28.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Teyro Labs Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Teyro Labs operates state-of-the-art manufacturing facilities designed to meet international regulatory standards. The primary manufacturing plant, located in Oragadam, Chennai, is dedicated to the production of oncology finished dosage forms, including liquid and lyophilized injectables, tablets, and capsules. This facility spans approximately 11 acres and comprises two independent manufacturing blocks: one for oncology finished dosage forms and another for liquid and lyophilized injectables. The plant utilizes advanced technologies such as Isolator technology and Restricted Access Barrier Systems (RABS) to ensure containment control and sterile assurance.

In addition to the Oragadam facility, Teyro Labs has an API and biotech manufacturing plant situated in the SIPCOT Industrial Complex in Kadikadu, Cuddalore, Tamil Nadu. This facility is under commissioning and is expected to be operational by the end of 2024. It is designed to produce oncology APIs, large and small volume general APIs, and fermentation-based immunosuppressant APIs and enzymes.

3Key Leadership

Teyro Labs is led by a team of experienced professionals committed to driving the company's growth and operational excellence. The current directors include Jagathrakshakan Swamikannu, who joined on August 18, 2023, and Sundeep Anand Jegathrakshagan, who has been serving since December 1, 2014. The company's leadership team is dedicated to steering Teyro Labs towards its vision of becoming a leading specialty pharmaceutical company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Teyro Labs Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Teyro Labs has established a significant presence in several highly regulated international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company is registered with the US Food and Drug Administration (FDA), holding the Facility Establishment Identifier (FEI) number 3021389808, which underscores its compliance with stringent US regulatory standards.

In Europe, Teyro Labs has initiated the process for European Good Manufacturing Practice (EU GMP) certification, with inspections by the German Federal Institute for Drugs and Medical Devices (BfArM) scheduled for November 2023. This certification is crucial for market access in EU member states.

The company's manufacturing facilities are designed to meet international regulatory requirements, including those of the US FDA, MHRA, TGA, and WHO, facilitating market access in these regions.

2Emerging Markets

Teyro Labs has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company has initiated product registrations and market entries in countries such as Argentina, Brazil, Mexico, South Africa, Egypt, the United Arab Emirates, Saudi Arabia, and several Southeast Asian nations, including China, the Philippines, Indonesia, and Malaysia. This global expansion reflects Teyro Labs' commitment to providing accessible and affordable healthcare solutions worldwide.

Teyro Labs Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Teyro Labs' manufacturing facilities are registered with the US FDA, holding the Facility Establishment Identifier (FEI) number 3021389808. This registration indicates the company's compliance with FDA regulations, facilitating the export of its pharmaceutical formulations to the United States.

2WHO & EU GMP

Teyro Labs has initiated the process for obtaining European Good Manufacturing Practice (EU GMP) certification, with inspections by the German Federal Institute for Drugs and Medical Devices (BfArM) scheduled for November 2023. This certification is essential for market access in EU member states.

3CDSCO & Indian Regulatory

Teyro Labs holds a Certificate of Registration from the Department of Scientific & Industrial Research (DSIR), Government of India, and has obtained cGMP certification from the Drugs Control Administration, Government of Tamil Nadu, as well as from the Central Drugs Standard Control Organisation (CDSCO) and the World Health Organization (WHO). These certifications affirm the company's adherence to national and international regulatory standards.

Teyro Labs Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Teyro Labs operates in the highly competitive oncology pharmaceutical sector, facing competition from both established multinational corporations and emerging regional players. The company's focus on niche, high-potent formulations and its commitment to quality and regulatory compliance position it favorably in the market. While specific market share data is not publicly available, Teyro Labs' strategic initiatives and global expansion efforts indicate a strong competitive stance.

2Key Differentiators

Teyro Labs' key differentiators include its specialized focus on oncology products, a vertically integrated approach encompassing research, development, and manufacturing, and a commitment to meeting international regulatory standards. The company's state-of-the-art manufacturing facilities, equipped with advanced technologies like Isolator technology and RABS, ensure high-quality production. Additionally, Teyro Labs' proactive expansion into emerging markets demonstrates its agility and responsiveness to global healthcare needs.

3Strategic Position

Teyro Labs' current strategic direction emphasizes the development and manufacturing of specialty pharmaceutical formulations, particularly in the oncology segment. The company's focus on high-potent products and its commitment to regulatory compliance underscore its dedication to quality and patient safety. Looking ahead, Teyro Labs aims to expand its global footprint by entering new markets and enhancing its product portfolio, positioning itself as a leading player in the international pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Teyro Labs Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Teyro Labs has demonstrated a strong track record in pharmaceutical manufacturing, with a focus on oncology products. The company's export volume and consistency are evidenced by its presence in multiple international markets, including the US, EU, UK, Australia, and various countries in Africa, Latin America, and Southeast Asia. Teyro Labs' adherence to international regulatory standards and its proactive approach to quality management further enhance its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance and quality standards:

FDA Registration: Confirm the company's registration with the US FDA by checking the FDA's Establishment Registration and Device Listing database.

WHO-GMP Certification: Verify the WHO-GMP certification through the World Health Organization's official website or by contacting the WHO directly.

Frequently Asked Questions — Teyro Labs Private Limited

How many pharmaceutical products does Teyro Labs Private Limited export from India?

Teyro Labs Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Carboplatin ($934.6K), Pazopanib ($282.3K), Sunitinib ($89.5K). Total export value is $1.3M.

What is Teyro Labs Private Limited's total pharmaceutical export value?

Teyro Labs Private Limited's total pharmaceutical export value is $1.3M, based on 39 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Teyro Labs Private Limited cover?

Teyro Labs Private Limited exports across 2 therapeutic categories. The largest are Oncology (71.5%, 1 products), Advanced Oncology (28.5%, 2 products).

Get Full Teyro Labs Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.